Patent Extension Approved for Biological Product POMBILITI
Published Date: 6/16/2025
Notice
Summary
The FDA has officially set the review period for POMBILITI, a new human biological product. This means the company can apply to extend its patent, giving them more time to protect their invention. If approved, this could affect when generic versions hit the market and impact related business timelines and profits.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Patent Extension Application Filed
The FDA determined the regulatory review period for POMBILITI, a human biological product, and the company has submitted an application to the U.S. Patent and Trademark Office to extend a patent claiming that product. This notice means the patent holder can pursue extra patent term protection for POMBILITI.
Possible Delay in Generic Market Entry
If the patent extension for POMBILITI is approved, generic versions could come to market later than they otherwise would. You may face delayed access to lower-cost generic alternatives and related effects on business timelines and profits for other companies.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in